Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Native American participant enrolled from any of the clinical sites of the Johns Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk conditions for pneumococcal disease listed below, OR Native American participant enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1 of the following risk conditions for pneumococcal disease:~  1. Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) \<10%~ 2. Chronic liver disease with documented history of compensated cirrhosis (Child-Pugh Score A)~ 3. Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3~ 4. Confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed therapy~ 5. Confirmed diagnosis of chronic heart disease (New York Heart Association \[NYHA\] heart failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due to reduced or preserved ejection fraction or due to non-cyanotic congenital heart disease.~ 6. Current smoker~* Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after last administration of study vaccine.~Exclusion Criteria:~* History of active hepatitis within the prior 3 months~* History of diabetic ketoacidosis, or \>1 episodes of severe, symptomatic hypoglycemia within the prior 3 months~* Myocardial infarction, acute coronary syndrome, transient ischemic attack, and ischemic or hemorrhagic stroke within the prior 3 months~* History of severe pulmonary hypertension or history of Eisenmenger syndrome~* History of invasive pneumococcal disease (IPD) or known history of other culture-positive pneumococcal disease within the prior 3 years~* Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or diphtheria toxoid-containing vaccine~* Known or suspected impairment of immunological function (including human immunodeficiency virus (HIV) infection or autoimmune disease)~* History of malignancy within the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome~* History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months~* History of coagulation disorder contraindicating intramuscular vaccination~* History of hospitalization within the prior 3 months~* Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgery during the duration of this study.~* Expected survival for less than 1 year according to the investigator's judgment.~* Female participant: positive urine or serum pregnancy test~* Prior administration of any pneumococcal vaccine~* Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed within the prior 30 days~* Received systemic corticosteroids exceeding physiologic replacement doses within 14 days before study vaccination~* Receiving immunosuppressive or immunomodulatory therapy with a biological agent~* Received any licensed, non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of study vaccine~* Received any live vaccine within 30 days before receipt of any study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine~* Received a blood transfusion or blood products within the prior 6 months~* Receiving chronic home oxygen therapy~* Participated in another clinical study of an investigational product within the prior 2 months~* Current user of recreational or illicit drugs or history of drug abuse or dependence~* Diabetes mellitus with HgA1c ≥10%~* Chronic liver disease with Child-Pugh Class B or C cirrhosis~* Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma~* Chronic heart disease with NYHA heart failure Class 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete